Stocksigma LogoStocksigma Logo

Q-Line Biotech Reports H1 FY27 Results with 10% EBITDA Growth and Strategic Acquisition

Q-Line Biotech reported consolidated revenue of ₹152.18 crore for H1 FY27, up 5.83% YoY, while EBITDA rose 10.02% YoY to ₹39.57 crore with margins

Q-Line Biotech Reports H1 FY27 Results with 10% EBITDA Growth and Strategic Acquisition

Q-Line Biotech Ltd · Press Release · 13 Nov 2026, 2:16 am

Q-Line Biotech Reports H1 FY27 Results with 10% EBITDA Growth and Strategic Acquisition Q-Line Biotech reported consolidated revenue of ₹152.18 crore for H1 FY27, up 5.83% YoY, while EBITDA rose 10.02% YoY to ₹39.57 crore with margins expanding 99 bps to 26.00%. PAT declined 8.06% YoY to ₹19.60 crore, impacted by higher depreciation from the newly capitalized Unit 4 facility and finance costs. Reagent sales grew 19.23% YoY and trade business surged 20.13% YoY. Additionally, the Board approved acquiring a 70% stake in Heidelco Medicore for ₹26.63 crore to consolidate operations and drive synergies.

Original exchange filing (PDF)

More announcements from Q-Line Biotech Ltd

All Q-Line Biotech Ltd announcements